PT - JOURNAL ARTICLE AU - Katri Korpela AU - Roosa Jokela AU - Ching Jian AU - Evgenia Dikareva AU - Anne Nikkonen AU - Terhi Saisto AU - Kirsi Skogberg AU - Willem M. de Vos AU - Kaija-Leena Kolho AU - Anne Salonen TI - Quantitative insights into effects of intrapartum antibiotics and birth mode on infant gut microbiota in relation to well-being during the first year of life AID - 10.1101/2021.11.01.21265735 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.01.21265735 4099 - http://medrxiv.org/content/early/2021/11/01/2021.11.01.21265735.short 4100 - http://medrxiv.org/content/early/2021/11/01/2021.11.01.21265735.full AB - Background and aims Caesarean section (CS)-birth and maternally administered intrapartum antibiotics (IP) affect colonization of the neonate. We compared the effects of CS delivery and IP antibiotics on infant gut microbiota development and wellbeing over the first year. To understand the developing community dynamics, we focused on absolute bacterial abundance estimates over relative abundances.Methods We studied 144 healthy infants born between gestational weeks 37-42 vaginally without antibiotics (N=58), with IP penicillin (N=25) or cephalosporin (N=13), or by CS with IP cephalosporin (N=34) or other antibiotics (N=14). Gut microbiota composition and temporal development was analysed at 5-7 time points during the first year of life using 16S rRNA gene amplicon sequencing, complemented with qPCR to obtain absolute abundance estimates in 92 infants. A mediation analysis was carried out to identify taxa linked to gastrointestinal function and discomfort (crying, defecation frequency and signs of gastrointestinal symptoms) and birth interventions.Results Based on absolute abundance estimates, depletion of Bacteroides spp. was specific to CS birth while decreased bifidobacteria and increased Bacilli were common to CS birth and exposure to IP antibiotics in vaginal delivery. Abundance of numerous taxa differed between the birth modes among cephalosporin-exposed infants. Penicillin had a milder impact on the infant gut microbiota than cephalosporin. The effects of both CS birth and IP antibiotics on infant gut microbiota associated with increased gastrointestinal symptoms during the first months.Conclusion CS birth and maternal IP antibiotics have both specific and overlapping effects on infant gut microbiota development. The resulting microbiota deviations were found to associate with gastrointestinal symptoms in infancy.Background and Context Birth mode and maternal intrapartum antibiotics affect infant’s gut microbiota development but their relative contribution, and effects on absolute bacterial abundances and infant health remain unknown.New Findings Utilizing quantitative microbiota profiling, we identified shared and unique microbiota effects of birth mode and intrapartum antibiotics which explained up to 54% of variation in parent-reported gastrointestinal symptoms in infants.Limitations Due to the limited sample sizes, especially during the first weeks of life, stratified analyses according to antibiotic dosing could not be performed, and the results on gastrointestinal symptom-microbiota-associations are tentative.Impact Birth mode overrules the effects of maternal antibiotics on infant microbiota development, while both birth mode and maternal antibiotic use are associated to common functional gastrointestinal symptoms in infancy.Lay summary Caesarean-section birth and maternal antibiotics during vaginal birth affect infant’s gut microbiota and may increase gastrointestinal discomfort.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by grants from Tekes 329/31/2015 (Health and the Early Life Microbiome (WMdV), Academy of Finland 1297765 (KK) and 1325103 (AS), Pediatric Research Foundation, Finland and Helsinki University Hospital Grant (KLK), The Paulo and Sohlberg Foundations (AS) and the Doctoral Program in Microbiology and Biotechnology, University of Helsinki, Finland funding (RJ).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies were approved by the ethical committee of The Hospital District of Helsinki and Uusimaa and performed in accordance with the principles of the Helsinki Declaration.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe sequencing data will be deposited upon acceptance of the article to European nucleotide Archive.AICAkaike information criterionANOVAAnalysis of varianceCepCephalosporinCRPC-reactive proteinCSC-section, Caesarean sectionGBSGroup B StreptococcusGIGastrointestinalHELMiFinnish Health and Early Life MicrobiotaHMOHuman milk oligosaccharideIPIntrapartumNGSNext generation sequencingPCoAPrincipal coordinate analysisPenPenicillinrRNARibosomal ribonucleic acidSCFAShort-chain fatty acidsVASVisual analogue scaleVDVaginal deliveryqPCRQuantitative polymerase chain reaction